CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Kindeva Drug Delivery

Nicholas Smalley, Vice President of Regulatory Affairs

From Complex to Compliance: 3 Keys for Unlocking the Regulatory Pathway

Nicholas Smalley

Nicholas Smalley

.

The pharmaceutical industry spends billions of dollars on R&D every year, resulting in an interesting and dynamic business where innovative new ideas and concepts to improve human health are created daily. However, one of the biggest challenges of this on-going innovation for the regulatory professional is how to guide organizations to effectively develop their newest complex drug product so it can be approved for use. Across my career, I have found three key things help navigate this process:


1. Do the Right Thing


At the very end of every pharmaceutical development is a patient. It might be you, your parents, or your children, so even where guidance is available, the priority should be to maximise the benefit while minimising the risk. From concept to launch, developing a new drug product is risky, so you must base your programme on doing the right thing.


Most regulatory guidance is grounded in history and what has come before, so it may not apply to your novel technology. In the absence of specific guidance or in the struggle to balance conflicting requirements, I have found the soundest position from which to start is putting the patient first. Always challenge yourself by asking, “Are we doing the right thing?”


Regulatory regimens are only interested in your product's quality, safety, and efficacy. So, if you can justify that your development programme is in the patient's best interests, then you stand a much better chance of getting regulator agreement and approval, irrespective of any prevailing guidance. In this situation, the regulatory professional's skill is putting together patient-centric justification and explaining why what was done was the right choice.


2. Collaborate and Network


Most regulatory authorities are reactive rather than proactive regarding guidance and advice, so regulatory professionals need to empower themselves to guide their companies through the development minefield. One of the best ways to do this is never to miss an opportunity to interact with regulators. 


Many regulatory authorities have pre-submission or pre-development meetings, which are excellent opportunities to explain a new product and highlight the potential patient benefit.


On a more general note, regulators often speak at conferences, and many authorities run their seminars on various topics, so build your network whenever you can. Take every opportunity to get to know your regulators and strengthen that critical regulatory partnership. You may not get all the answers you want from these interactions.


Nonetheless, early and regular engagement with regulators gives you a seat at the table, which becomes particularly important when you have something novel to discuss. You will have multiple opportunities to educate regulators throughout the development and licensing process, but it is best to begin your regulatory collaboration early, before data submission or before they are generated.


One of the biggest challenges of this on-going innovation for the regulatory professional is how to guide organizations to effectively develop their newest complex drug product so it can be approved for use.


3. Create Clarity


Always remember that you are the expert on your technology or product, not the regulators. Many regulatory professionals mistakenly believe that questions from authorities come from a position of wisdom and greater knowledge. They incorrectly assume that regulators clearly understand everything they are presented with, so questions from them must be a critique.


It is likely that regulator questions come simply from insufficient understanding and a lack of clarity regarding the information presented. Sometimes, the issue is one of terminology, as an entirely new technology improperly explained offers false or insufficient understanding for regulators. The best regulatory professionals can clearly explain their product and its benefits in language that regulators understand and can point regulators to the data supporting their arguments.


Seeking Success


Regulatory professionals are the essential link connecting product development and compliance, ensuring both are synchronised throughout an often lengthy process. By ensuring solid communication with regulators and remaining committed to patients' best interests, there is an opportunity to smooth the pathway. While the process can be complex, your new product will benefit the world, so every effort you make to approve it is worthwhile.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cxoinsight/from-complex-to-compliance-3-keys-for-unlocking-the-regulatory-pathway-nwid-1530.html